

Neurology Medical Group of Diablo Valley  
108 La Casa Via  
Suite 105  
Walnut Creek, CA 94598  
Phone: 925-939-9400  
Fax: 925-939-1819

## Steven Jay Holtz , MD

### Certifications

American Board of Psychiatry and Neurology - Neurology (Diplomate)	1981
National Board of Medical Examiners (Diplomate)	1975

### Licensure

Primary MD - G30609, California

### Academic Degrees

MD - Boston University, Boston, MA	1974
AB - Boston University, Boston, MA	1972

### Residencies and Internships

Resident - Internal Medicine, Kaiser Foundation Hospital, Oakland, CA	June 1975 - June 1976
Resident - Neurology, Jr & Sr, Boston University Affiliated Hospitals Training Program, Boston, MA	July 1976 - June 1979

### Academic Appointments

Associate Clinical Professor – Neurology, University of California San Francisco Medical School, San Francisco, CA	1999 – present
Clinical Faculty Representative – Neurology, Association of the Clinical Faculty, University of California San Francisco Medical School, San Francisco, CA	
Adjunct Assistant Professor – Samuel Merritt College, Oakland, CA	1990 – 1999
Clinical Preceptor – Health & Medical Apprenticeship Program, University of California Berkeley, Berkeley, CA	1985 – present
Assistant Clinical Professor – Neurology, University of California Davis, Davis, CA	1983 – present
Assistant Clinical Professor – Neurology, University of California San Francisco Medical School, San Francisco, CA	1981 – present
Teaching Fellow in Neurology – Boston University School of Medicine, Boston, MA	1976 – 1979

### Professional Societies

National Stroke Association	1992 – present
American Society of Neurorehabilitation	1992 – present

American College of Legal Medicine	1992 – present
Stroke Council, American Heart Association - Fellow	1991 – present
Epilepsy Foundation Northern California	1987 – present
San Francisco Neurological Association	1980 – present
California Medical Association	1979 – present
Alameda-Contra Costa Medical Association	1979 – present
American Academy of Neurology	1976 – present
American College of Physicians	1975 – present

### **Experience**

Private Practice of Neurology – Neurology Medical Group of Diablo Valley, Walnut Creek, CA	1980 – present
--	----------------

### **Appointments**

Attendee & Participant – Conferences, Seminars and Continuing Education in Multiple Sclerosis	ongoing
Ongoing Involvement – Multiple Sclerosis Patient Support Groups	present
Medical Director – Brain Injury Program, Guardian of Concord, Concord, CA	1996 – present
Chairman – Medical Advisory Board, Epilepsy Foundation of Northern California	1992 – present
Member – Legal Affairs Committee, American Academy of Neurology	1992 – present
Member – Neurology Panel Commission on Peace Officer Standards & Training, Dept. of Justice, State of California	1992 – present
Member – Neurology Advisory Committee, Kentfield Rehabilitation Hospital, Kentfield, CA	1991 – present
Qualified Medical Examiner, #003060	1991 – present
Medical Advisory Board – Multiple Sclerosis Society, Northern California	1988 – present
Medical Director – Alzheimer's Unit, Crestwood Treatment Center, Pleasant Hill, CA	1988 – present
Medical Advisory Board – Mt. Diablo Rehabilitation Center, Pleasant Hill, CA	1983 – present
Medical Advisor – Stroke Support Group, Contra-Costa County, Walnut Creek & Concord, CA	1983 – present
Consultant, Neurorehabilitation – Golden State Rehabilitation Hospital, San Ramon, CA	1989 – 1995
Consultant, Neurorehabilitation – Contra Costa Rehabilitation Center, Pittsburg, CA	1993 – 1994
Medical Director – Neurocare, Inc., Rehab. Without Walls, Concord, CA	1993
Medical Director – Stroke Rehabilitation Program, Golden State Rehabilitation Hospital, San Ramon, CA	1989 – 1993
Medical Staff President – Golden State Rehabilitation Hospital, San Ramon, CA	1990 – 1992
Medical Director – Alzheimer's Disease Program, Mt. Diablo Rehabilitation Center, Concord, CA	1985 – 1989
Consultant – National Institute of Neurological & Communicative Disorders & Stroke – NIH, Bethesda, MD	1986
Medical Director – Head Injury Program, Mt. Diablo Rehabilitation Center, Concord, CA	1983 – 1986
Medical Director – Neurology, Paradigm Health Corporation, Concord, CA	

### **Awards**

Outstanding Teacher in Clinical Preceptorship – University of California San Francisco Medical School, San Francisco, CA	1987 – 1992
--	-------------

### **Current Hospital Affiliations**

John Muir Medical Center – Walnut Creek, CA  
Mt. Diablo Medical Center – Concord, CA  
Guardian San Ramon Rehabilitation Hospital – San Ramon, CA  
Walnut Creek (Psychiatric) Hospital – Walnut Creek, CA

### **Presentations & Publications**

Holtz SJ, "Nerve Injury From Exposure to Drugs." American Jurisprudence Proof of Facts, 3d Series, Volume 15, Lawyers Cooperative Publishing, 1992.

Holtz SJ, "Nerve Injury From Exposure to Industrial Agents." American Jurisprudence Proof of Facts, 3d Series, Volume 16, Lawyers Cooperative Publishing, 1992.

Holtz SJ, "Nerve Injury From Exposure to Toxic Metals." American Jurisprudence Proof of Facts, 3d Series, Volume 14, Lawyers Cooperative Publishing, 1991.

Holtz SJ, "Peripheral and Cranial Nerve Injury due to Trauma." American Jurisprudence Proof of Facts, 3d Series, Volume 10, Lawyers Cooperative Publishing, 1990.

Holtz SJ, "Gammopathy with Proximal Motor Axonopathy Simulating Motor Neuron Disease." Neurology, 36: 273-276, 1986.

### **Research Activities**

#### **PRINCIPAL INVESTIGATOR**

An Open-Label Study to Evaluate the Safety and Efficacy of 1.5 mg b.i.d. (3 mg/day) through 6 mg b.i.d.(12 mg/day) of Exelon in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting." 1997 – 1999

#### **SUBINVESTIGATOR**

A double-blind, active and placebo-controlled study of Aggrenox® vs. Clopidogrel + aspirin, with and without Micardis® (PROFESS) 2003 – present

A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess The Efficacy and Safety of Intravenous NXY-059 In Acute Ischemic Stroke (SAINT II) 2003 – present

A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron® 250µg Subcutaneously Every Other Day with Avonex® 30µg Intramuscularly Once per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated with Avonex® (ABOVE) 2003 – 2005

A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Fixed Dose Response Study Comparing the Efficacy and Safety of Sumanrole versus Placebo in Patients with Early Parkinson's Disease	2003 - 2005
E2020-A001-319 A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease	2003– 2004
A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects with Relapsing Multiple Sclerosis (MS) (PROOF)	2003 – 2004
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)	2003 – 2005
Phase I, A Single Rising Dose Study of FK506 Lipid Complex (LCG) in Patients With Recent Ischemic Stroke	2002 – 2004
Medical Index for Neuromuscular Data (MIND) Registry	2002 – 2005
A Multi-Center, open-label, randomized, 4-way crossover trial of the safety and Efficacy of Tizanidine Hydrochloride Capsules versus Zanaflex® (Tizanidine Hydrochloride) Tablets taken under fed and fasted conditions in patients with Moderate to severe Spasticity	2002
A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanrole versus Placebo or Ropinrole in Patients with Early Parkinson's Disease	2002 – 2003
Open-Label, Long-Term, Flexible Dose Study of Safety, Tolerability and Therapeutic Response in Patients with Parkinson's Disease: PNU-95666E	2002 – 2004
Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack or Ischemic Stroke: A Randomized, Double-Blind Study, With 18 Months Follow-up. (MATCH)	2001 – 2004
A Randomized, Placebo-Controlled, Three Treatment Arm Study to Determine the Safety and Efficacy of Argatroban Injection in Patients with Acute Ischemic Stroke	2001 – 2002
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of YM872 on Lesion Volume as Measured by Diffusion, Perfusion and FLAIR Magnetic Resonance Imaging in Patients with Acute Ischemic Stroke. (ARTIST MRI)	2001 - 2003
Multicenter, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients with Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Activator Plus Placebo. (ARTIST +)	2001 - 2003
Phase III Multicenter, Double-Blind, Parallel-Group Placebo Controlled Study of the Effect of Riluzole 50 mg BID or 100 mg BID on the Progression of Parkinson's Disease in Patients Treated with L-Dopa or Dopamine Agonist	2001

Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Latranal Compared to Doxepin Cream and Placebo in Patients with Chronic Low Back Pain	2001
Phase II, 12 Week, Randomized, Double-Blind, Placebo Controlled, Multicenter Study Evaluating the Safety and Efficacy of Three Fixed Doses of Oral CP-457,920 (30 mg QD, 60 mg BID and 120 mg BID) and Donepezil in Outpatients with Alzheimer's Disease	2000 – 2002
Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin©) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V)	2000 – 2003
Acute Ischemic Stroke Protocol 161-106, Phase II	2000
"Blockade of the GP IIB/IIIa Receptor to Avoid Vascular Occlusion (BRAVO), Phase III."	1999 – 2001
"A Phase III, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Hu23F2G (LeukArrest™) in Patients with Acute Ischemic Stroke"	1999 – 2000
"The Safety and Efficacy of MK-0966 in Slowing the Progression of the Symptoms of Alzheimer's Disease"	1999 – 2000
Lamictal® in Combination with Newer and Older Antiepileptic Drugs and as Monotherapy: A Practical Clinical Assessment of Tolerability and Clinical Effectiveness (The TARGET Study: <u>T</u> rial to <u>A</u> ssess and <u>R</u> efine <u>G</u> lobal <u>E</u> pilepsy <u>T</u> reatment)"	1999 – 2000
Pregabalin BID, Open-Label, Add-On Trial: "An Open-Label, Multicenter, Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures."	1998 – 2005
"Topamax Monotherapy Comparison Trial to Standard Monotherapy in the Treatment of Newly Diagnosed Epilepsy."	1998 – 2000
"A 4-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Three Dose Levels of Prosaptide When Administered Daily for 28 Days by Subcutaneous Injection on Diabetic Painful Neuropathy in Patients with Type 1 or Type 2 Diabetes Mellitus."	1998 – 1999
Pregabalin BID Add-On Trial: "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study in Patients with Partial Seizures."	1998 – 1999
The Acute Stroke Study in Ischemic Stroke (Class-I): "A Double-Blind, Parallel-Group, Multinational, Multicenter Study of the Efficacy and Safety of IV Compound Compared to Placebo in Patients with Acute Ischemic Stroke."	1997 – 2000
The Acute Stroke Study in Acute Intracerebral Hemorrhage (Class-H): A Double-Blind, Parallel-Group, Multinational, Multicenter Study of Safety of IV Compound Compared to Placebo in Patients with Acute Intracerebral Hemorrhage."	1997 – 1999

The Acute Stroke Study in t-PA Treated Ischemic Stroke (Class-T): "A Double-Blind, Parallel-Group, Multinational, Multicenter Study of the Safety of IV Compound Compared to Placebo in Patients Treated with t-PA (Tissue Plasminogen Activator) for Acute Ischemic Stroke."	1997 – 1999
"Enlimomab Acute Stroke Study, Phase III."	1995 – 1996
"DHE 454 Migraine Study, Phase III."	1995